Literature DB >> 22212078

Histological variants of prostatic carcinoma and their significance.

Peter A Humphrey1.   

Abstract

The vast majority of prostatic cancers are acinar adenocarcinomas. Histological variants of prostatic carcinoma have been variably defined. One approach is to consider two groups of variants. The first group comprises histological variants of acinar adenocarcinoma and the second group non-acinar carcinoma variants or types. Variants of usual acinar adenocarcinoma defined in 2004 by the World Health Organization (WHO) include atrophic, pseudohyperplastic, foamy, colloid, signet ring, oncocytic and lymphoepithelioma-like carcinomas. The second group of non-acinar carcinoma histological variants or types of prostatic carcinoma accounts for about 5-10% of carcinomas that originate in the prostate. These include sarcomatoid carcinoma, ductal adenocarcinoma, urothelial carcinoma, squamous and adenosquamous carcinoma, basal cell carcinoma, and neuroendocrine tumours, specifically small-cell carcinoma. Recently characterized variants not present in the 2004 WHO classification, including microcystic adenocarcinoma, prostatic intraepithelial neoplasia-like adenocarcinoma, large-cell neuroendocrine carcinoma, and pleomorphic giant cell carcinoma, are also described. The aims of this review are to present the essential histomorphological diagnostic attributes of these variants, and to emphasize the clinical signficance of the variants, when different from usual acinar adenocarcinoma, including clinical presentation and outcome.
© 2011 Blackwell Publishing Limited.

Entities:  

Mesh:

Year:  2012        PMID: 22212078     DOI: 10.1111/j.1365-2559.2011.04039.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  79 in total

1.  Prostatic ductal adenocarcinoma: an aggressive tumour variant unrecognized on T2 weighted magnetic resonance imaging (MRI).

Authors:  Nicola Schieda; Niamh Coffey; Previn Gulavita; Omran Al-Dandan; Wael Shabana; Trevor A Flood
Journal:  Eur Radiol       Date:  2014-04-01       Impact factor: 5.315

Review 2.  Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Authors:  Christopher J Logothetis; Gary E Gallick; Sankar N Maity; Jeri Kim; Ana Aparicio; Eleni Efstathiou; Sue-Hwa Lin
Journal:  Cancer Discov       Date:  2013-06-28       Impact factor: 39.397

3.  Ductal and Acinar Adenocarcinoma of Prostate: Morphological and Immunohistochemical Characterization.

Authors:  Faraz A Baig; Amna Hamid; Talat Mirza; Serajuddaula Syed
Journal:  Oman Med J       Date:  2015-05

Review 4.  Mouse models of prostate cancer: picking the best model for the question.

Authors:  Magdalena M Grabowska; David J DeGraff; Xiuping Yu; Ren Jie Jin; Zhenbang Chen; Alexander D Borowsky; Robert J Matusik
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

5.  Distinct phases of human prostate cancer initiation and progression can be driven by different cell-types.

Authors:  Tanya Stoyanova; Andrew S Goldstein
Journal:  Cancer Cell Microenviron       Date:  2014

Review 6.  The pathology of unusual subtypes of prostate cancer.

Authors:  Jing Li; Zhe Wang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

7.  2,3,7,8-Tetrachlorodibenzo-p-dioxin has both pro-carcinogenic and anti-carcinogenic effects on neuroendocrine prostate carcinoma formation in TRAMP mice.

Authors:  Robert W Moore; Wayne A Fritz; Andrew J Schneider; Tien-Min Lin; Amanda M Branam; Stephen Safe; Richard E Peterson
Journal:  Toxicol Appl Pharmacol       Date:  2016-05-03       Impact factor: 4.219

8.  Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.

Authors:  Tanya Stoyanova; Aaron R Cooper; Justin M Drake; Xian Liu; Andrew J Armstrong; Kenneth J Pienta; Hong Zhang; Donald B Kohn; Jiaoti Huang; Owen N Witte; Andrew S Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-26       Impact factor: 11.205

9.  Ductal variant of prostate adenocarcinoma harbor Xenotropic murine leukemia virus related virus (XMRV) infection: a novel finding in subtype of prostate cancer.

Authors:  Faraz Ahmed Baig; Talat Mirza; Amna Hamid; Serajuddaula Syed; Qamar Jamal
Journal:  Turk J Urol       Date:  2017-07-31

10.  Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma.

Authors:  Joe H Chang; Daryl Lim Joon; Sze Ting Lee; Chee-Yan Hiew; Stephen Esler; Sylvia J Gong; Morikatsu Wada; David Clouston; Richard O'Sullivan; Yin P Goh; Henri Tochon-Danguy; J Gordon Chan; Damien Bolton; Andrew M Scott; Vincent Khoo; Ian D Davis
Journal:  Eur Radiol       Date:  2013-11-06       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.